SCHEMBL4975796

SCHEMBL4975796

COc1ccc2ncn(CCO)c2c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRPS1 P60891 3/20 0.55
DPP4 P27487 2/20 0.47
DPP8 Q6V1X1 1/20 0.47
HASPIN Q8TF76 1/20 0.39
DYRK2 Q92630 1/20 0.39
LMNA P02545 1/20 0.38
ADORA2B P29275 1/20 0.38
GLP1R P43220 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KDR P35968 1/20 0.36
P2RX3 P56373 1/20 0.36
FGFR1 P11362 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
SRC P12931 1/20 0.36
TNF P01375 1/20 0.35
IDO1 P14902 1/20 0.35
MAPT P10636 1/20 0.35
PDE4A P27815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975758 0.80 HDAC6 (0.53) PRPS1ADORA2BALDH1A1KDRHDAC6
SCHEMBL307128 0.77 DPP4 (0.50) PRPS1DPP4DPP8LMNAADORA2B
SCHEMBL307323 0.73 DPP4 (0.52) PRPS1DPP4DPP8LMNAADORA2B
SCHEMBL23227615 0.72 PRPS1 (1.00) PRPS1
SCHEMBL308832 0.72 DPP4 (0.58) PRPS1DPP4DPP8LMNAADORA2B
SCHEMBL20472703 0.72 PRPS1 (0.71) PRPS1
Hydrochloric Acid SCHEMBL23227701 0.71 PRPS1 (0.98) PRPS1
SCHEMBL9598443 0.71 MEN1 (0.49) PRPS1LMNAKDRFGFR1HDAC6
SCHEMBL308444 0.69 PRPS1 (0.51) PRPS1DPP4DPP8LMNAADORA2B
SCHEMBL12479232 0.69 MTNR1A (0.66) ALDH1A1FGFR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PRPS1 3714/4885DPP4 154/4885DPP8 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.